يُعرض باللغة الإنجليزية — الترجمة العربية قيد الإعداد
medical-blog
آخر تحديث: 2021-05-04

A Bridge Across Borders: Medical Supporter's Seamless Treatment Process in Japan

S
فريق Medical Supporter
فريق تنسيق طبي دولي ومراجعة تحريرية
A Bridge Across Borders: Medical Supporter's Seamless Treatment Process in Japan

A Bridge Across Borders: Medical Supporter's Seamless Treatment Process in Japan

Medical Supporter — إشعار معلوماتي

هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.

يجب أن يقيّم أي خطة علاج محددة طبيب مرخّص في اليابان

Seeking medical help in a foreign country is a major decision. The Medical Supporter team is not just your translator, but your professional partner on this journey. We combine Japan's rigorous medical standards with warm service to create these six peace-of-mind steps.

Step 1: Sincere Listening and Initial Consultation

Everything starts with your story. You can contact our consultants via online messaging tools or telephone. We will organize your medical history, imaging reports, and current physical condition to ensure we connect you with the most appropriate Japanese specialist system.

Step 2: Remote Evaluation by Authoritative Physicians (Second Opinion)

We translate your information into a professional Japanese format and submit it to top Japanese institutions (such as the National Cancer Center, University of Tokyo Hospital, etc.) for preliminary review. Physicians will determine if Japanese therapies (such as immunotherapy or particle beam therapy) can be beneficial based on current data.

Step 3: Transparent Treatment Plans and Budgeting

Once the hospital confirms acceptance, we provide a detailed medical plan. This includes estimated stay duration, treatment cycles, and transparent cost calculations. We adhere to the principle of hospital fees plus a 20% service fee, ensuring you have a clear grasp of every part of your budget.

Step 4: Dedicated Medical Visa (B-066) Processing

As a formerly certified guarantee agency by Japan's Ministry of Foreign Affairs and METI (B-066), we will issue the Guarantee of Identity for you, assisting you in obtaining a medical stay visa in the shortest possible time to ensure you and your family can legally and safely stay in Japan for treatment.

Step 5: Professional Medical Escort and Life Support in Japan

After arriving in Japan, our medical translators will accompany you throughout your visits, ensuring precise communication between you and the physicians. Meanwhile, we carefully manage accommodation arrangements, transportation, and special dietary needs, making you feel the warmth of home.

Step 6: Continuous Follow-up After Returning Home

The end of treatment does not mean the end of our service. After you return home, we will assist in reporting your Japanese examination results to your local physicians and regularly help schedule follow-up remote consultations to track your recovery status.


Your health, we protect it together. The professional team at Medical Supporter is on standby. If you wish to begin this journey, please click below to contact us.

هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟

نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.

المقر الرئيسي في فوكوكا: +81-92-984-3200
حاصل سابقًا على اعتماد رسمي، رقم B-066

Compliance Notice: Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

قراءة ذات صلة

Is OPDIVO Effective for Liver Cancer?

On December 13, 2021, Thomas Yau and colleagues from the University of Hong Kong published the results of the CheckMate 459 Phase III clinical trial in 'The Lancet Oncology,' evaluating the anti-PD-1 antibody OPDIVO (nivolumab) as a first-line treatment for advanced hepatocellular carcinoma.

2018-12-25

[Lung Cancer Precision Medicine] Crizotinib (Xalkori) Approved for ROS1-Positive Lung Cancer: A New Chapter in Target...

Although ROS1 gene abnormalities account for only about 1% of lung cancer patients, the successful development of Crizotinib provides this patient population with a highly effective treatment option. This article analyzes its clinical performance targeting ROS1 mutations and safety assessment.

2018-05-18

[Lung Cancer Advanced Treatment] A New Height in Immunotherapy: Tiragolumab Combined with Tecentriq Demonstrates Exce...

The CITYSCAPE Phase 2 clinical trial in PD-L1-positive advanced non-small cell lung cancer patients confirmed that anti-TIGIT antibody Tiragolumab combined with Tecentriq (Atezolizumab) significantly improves objective response rate and progression-free survival.

2020-12-19

Fukuoka Cancer Comprehensive Clinic: Apheresis Technology and Advanced Lymphocyte Immunotherapy

Fukuoka Cancer Comprehensive Clinic, led by Dr. Morisaki, maintains research partnership with Kyushu University. In-house CPC laboratory enables high-purity immune cell therapy via apheresis technology for middle to advanced cancer patients.

2018-07-30